Vascular diseases, which impair blood flow, lead to significant complications and morbidity. Current treatments often have limited efficacy or significant side effects, leaving a need for more targeted and effective therapies.

Aerpio Pharmaceuticals is dedicated to developing targeted therapies for vascular diseases, utilizing both small molecules and monoclonal antibodies. Their approach focuses on improving blood flow and mitigating the complications associated with these conditions. By targeting specific pathways involved in vascular dysfunction, Aerpio aims to provide more effective and safer treatment options for patients suffering from a range of vascular disorders. Their research seeks to address the unmet needs in vascular disease management by developing innovative therapeutic interventions.

Development of small molecule therapeutics targeting vascular pathways.

Research and development of monoclonal antibody therapies for vascular diseases.

Focus on improving blood flow in affected tissues.

Aim to reduce complications associated with vascular disorders.

The primary target audience includes patients suffering from various vascular disorders and the healthcare professionals who treat them, such as vascular surgeons, cardiologists, and internal medicine physicians.